Study of PCC1 for Skin Rejuvenation

A 12-week , Randomized, Open-label Study of PCC1 in Healthy Volunteers for Skin Rejuvenation

NCT06641869•Express Rx, Inc

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Skin Rejuvenation

Interventions

procyanidin C1

Placebo

+1 more

Locations

Switzerland

Locations (1)

University of Geneva

Geneva, Switzerland

Key Dates

Start Date

October 10, 2022

Primary Completion Date

February 23, 2024

Completion Date

August 10, 2024

Last Updated

August 11, 2025

Sponsors

Lead Sponsor

Express Rx, Inc

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 11, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions